Cuproptosis-immunity crosstalk informs strategy to overcome immunotherapy resistance.

作者：Guang Lei, Zhengze Lu, Zhihao Xu, Chen Braun, David Huo, Jian Gao, Lin Tan, Ting Hong, Shengrong Wu, Mingchuang Sun, Xi Zhao, Qidong Li, Xiong Chen, Yuelong Yan, Hyemin Lee, Chao Mao, L. Zhuang, Li-Ting Ku, N. Puebla, H. Barsoumian, Jun Yao, L. Hong, Jianjun Zhang, Hai Tran, Jiun-Kae Jack Lee, D. Gibbons, Ara Vaporciyan, J. Heymach, Chunru Lin, E. Gottlieb, M. J. You, James W. Welsh, Steven H. Lin, X. Zang, Ziyi Li, Boyi Gan · 发表于：Cell · 年份：2026 · DOI：10.1016/j.cell.2026.05.036 · 被引用次数：11 · 研究领域：Medicine

Cuproptosis is a recently identified form of copper-dependent cell death that depends on ferredoxin 1 (FDX1)-mediated protein lipoylation. Here, we reveal that CD8+ T cell-mediated antitumor immunity enhances tumor cell susceptibility to cuproptosis, leading to a more potent tumor-suppressive effect of cuproptosis inducers in immunocompetent hosts compared with immunodeficient ones. Mechanistically, cuproptotic tumor cells act as a form of immunogenic cell death, releasing damage-associated molecular patterns that activate dendritic cells and enhance antitumor immunity. Reciprocally, CD8+ T cell-derived interferon (IFN)-γ enhances FDX1 transcription in tumor cells by activating the signal transducer and activator of transcription 1 (STAT1)-IFN regulatory factor-1 (IRF1) signaling axis, resulting in heightened tumor cell sensitivity to cuproptosis. Consequently, combining a cuproptosis inducer with anti-programmed cell death ligand 1 (PD-L1) therapy amplifies tumoral cuproptosis and demonstrates efficacy in overcoming PD-L1 therapy resistance across multiple preclinical models. Our findings unveil a previously unrecognized connection between antitumor immunity and cuproptosis and highlight a potential therapeutic approach to counteract tumor immunotherapy resistance by targeting this unique cell death pathway.